Weekly Endocrinology Research Analysis
This week saw high-impact, cross-cutting advances: a pan-tissue single-cell Hormone Cell Atlas redefines endocrine cell networks and enables tissue-specific target discovery; a first-in-human in vivo base-editing therapy (VERVE-102) produced dose-dependent, durable PCSK9 and LDL-C reductions, signaling a potential one‑time genetic approach to lipid lowering; and translational work revealed a microbiota–melibiose–GLO1 axis mediating canagliflozin’s renoprotection, highlighting microbiome-targeted
Summary
This week saw high-impact, cross-cutting advances: a pan-tissue single-cell Hormone Cell Atlas redefines endocrine cell networks and enables tissue-specific target discovery; a first-in-human in vivo base-editing therapy (VERVE-102) produced dose-dependent, durable PCSK9 and LDL-C reductions, signaling a potential one‑time genetic approach to lipid lowering; and translational work revealed a microbiota–melibiose–GLO1 axis mediating canagliflozin’s renoprotection, highlighting microbiome-targeted adjuncts for diabetic kidney disease.
Selected Articles
1. A Hormone Cell Atlas maps the human endocrine system at cellular resolution.
A pan‑tissue single‑cell transcriptomic resource mapped 379 hormone and receptor genes across 14 million cells from 47 tissues using hormone2cell, identifying hormone‑producing and hormone‑receiving cell types, non‑classical hormone sites, cross‑tissue endocrine circuits, and dynamic adipocyte endocrine programs—creating an open resource to drive biomarker and target discovery.
Impact: Provides an unprecedented, open, systems‑level map that redefines endocrine circuits, directly enabling hypothesis generation for biomarkers, targets, and tissue‑specific therapies across endocrine diseases.
Clinical Implications: Facilitates more precise biomarker nomination and target validation (e.g., cell‑type specific hormone/receptor pairs), potentially accelerating diagnostic panels and tissue‑targeted interventions in endocrine disorders.
Key Findings
- Mapped 379 hormone and receptor genes across 14 million single cells/nuclei from 47 human tissues.
- Predicted non‑classical hormone expression sites (e.g., secretin in plasmacytoid dendritic cells) and cross‑tissue endocrine feedback loops.
- Uncovered dynamic, depot- and subtype-specific endocrine programs within adipocytes across adipogenesis.
2. In Vivo Base Editing of
In a phase 1 single‑ascending‑dose study (n=35), a one‑time in vivo adenine base‑editing therapy (VERVE‑102 delivered as mRNA + guide RNA) produced dose‑dependent, durable reductions in circulating PCSK9 (up to 88%) and LDL‑C (up to 62%, −78 mg/dL at highest dose) with no dose‑limiting toxicities over early follow‑up, suggesting a potential paradigm shift toward one‑time genetic LDL lowering.
Impact: First human evidence that targeted in vivo base editing can durably modify a circulating cardiovascular risk factor, opening a new therapeutic class with major public‑health implications if long‑term safety and efficacy are confirmed.
Clinical Implications: Pending phase 2/3 data, in vivo PCSK9 editing could become an option for patients with familial hypercholesterolemia or high ASCVD risk who are intolerant/ nonadherent to standard therapy; clinicians should monitor ongoing trials and potential long‑term safety signals (off‑target editing, immune events).
Key Findings
- Dose-dependent PCSK9 reductions (51% at 0.3 mg/kg to 88% at 1.0 mg/kg).
- Corresponding LDL‑C reductions of 9% to 62% (absolute −78 mg/dL at highest dose).
- No dose‑limiting toxicities; mild–moderate infusion reactions and transient ALT elevations observed.
3. Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota-Dependent Manner.
Human and mouse translational studies (human cohort n=170; 26 weeks) linked canagliflozin to gut microbiome remodeling (Roseburia intestinalis enrichment) and increased plasma melibiose; melibiose activated GLO1, lowered methylglyoxal and AGE–RAGE signaling, preserving glomerular endothelium. Fecal microbiota transplant, Roseburia or melibiose recapitulated protection in mice, and a melibiose precursor reduced albuminuria in early DKD patients, implicating a drug–microbiome–metabolite renoprotective axis.
Impact: Identifies a causal microbiota–metabolite mediator (melibiose) and druggable enzymatic target (GLO1) underlying SGLT2 inhibitor renal benefits, bridging human cohorts, gnotobiotic models, and biochemical target engagement—opening microbiome‑centric adjunct strategies.
Clinical Implications: Supports development of microbiome‑ or metabolite‑based adjuncts (melibiose precursors, Roseburia‑promoting interventions) to augment SGLT2 inhibitor effects in DKD; recommends randomized controlled trials to confirm efficacy, dose, and safety.
Key Findings
- Canagliflozin remodeled the gut microbiome and increased plasma melibiose in humans (n=170) over 26 weeks.
- Melibiose bound/activated GLO1, reduced methylglyoxal and suppressed AGE–RAGE signaling, preserving glomerular endothelium.
- FMT, Roseburia administration, or melibiose recapitulated renoprotection in mice; a melibiose precursor reduced albuminuria in early DKD patients.